Experimental therapeutic approaches to adenocarcinoma: The potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer

Lorenzo Mortara, Luca Giuliani, Andrea De Lerma Barbaro, Roberto S. Accolla, Douglas M. Noonan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We have previously shown that TS/A murine mammary adenocarcinoma cells, induced to express high surface expression of MHC class II molecules by stable transfection of CIITA, resulted in high rate (92%) of tumor rejection and tumor immunity to subsequent homologous tumor challenges. The immunological basis of tumor response is based on tumor-specific CD4+ T helper type 1 (Th1) in the priming phase and tumor-specific CD8+ T cells as the major effector cells. IL-12 is the crucial cytokine that drives Th1 polarization in conjunction with inducing strong cellular-based immune responses. We have previously shown in the same tumor model that a naked DNA IL-12 gene transfer was effective in preventing tumor angiogenesis in an immunopreventive approach when administrated at least 2 days prior to the tumor inoculation. Here we indicate that the combination of the two approaches in immunotherapy of established tumors is efficacious in delaying tumor growth but not in completely eradicating the tumor.

Original languageEnglish
Pages (from-to)33-36
Number of pages4
JournalSurgical Oncology
Volume16
DOIs
Publication statusPublished - Dec 2007

Fingerprint

Interleukin-12
Adenocarcinoma
DNA
Genes
Neoplasms
Therapeutics
Cellular Immunity
Immunotherapy
Transfection
Immunity
Breast
Cytokines
T-Lymphocytes

Keywords

  • Adenocarcinoma
  • IL-12
  • MHC-II

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Experimental therapeutic approaches to adenocarcinoma : The potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer. / Mortara, Lorenzo; Giuliani, Luca; De Lerma Barbaro, Andrea; Accolla, Roberto S.; Noonan, Douglas M.

In: Surgical Oncology, Vol. 16, 12.2007, p. 33-36.

Research output: Contribution to journalArticle

@article{3c8326b474ae4e37ba91beff51714251,
title = "Experimental therapeutic approaches to adenocarcinoma: The potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer",
abstract = "We have previously shown that TS/A murine mammary adenocarcinoma cells, induced to express high surface expression of MHC class II molecules by stable transfection of CIITA, resulted in high rate (92{\%}) of tumor rejection and tumor immunity to subsequent homologous tumor challenges. The immunological basis of tumor response is based on tumor-specific CD4+ T helper type 1 (Th1) in the priming phase and tumor-specific CD8+ T cells as the major effector cells. IL-12 is the crucial cytokine that drives Th1 polarization in conjunction with inducing strong cellular-based immune responses. We have previously shown in the same tumor model that a naked DNA IL-12 gene transfer was effective in preventing tumor angiogenesis in an immunopreventive approach when administrated at least 2 days prior to the tumor inoculation. Here we indicate that the combination of the two approaches in immunotherapy of established tumors is efficacious in delaying tumor growth but not in completely eradicating the tumor.",
keywords = "Adenocarcinoma, IL-12, MHC-II",
author = "Lorenzo Mortara and Luca Giuliani and {De Lerma Barbaro}, Andrea and Accolla, {Roberto S.} and Noonan, {Douglas M.}",
year = "2007",
month = "12",
doi = "10.1016/j.suronc.2007.10.045",
language = "English",
volume = "16",
pages = "33--36",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Experimental therapeutic approaches to adenocarcinoma

T2 - The potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer

AU - Mortara, Lorenzo

AU - Giuliani, Luca

AU - De Lerma Barbaro, Andrea

AU - Accolla, Roberto S.

AU - Noonan, Douglas M.

PY - 2007/12

Y1 - 2007/12

N2 - We have previously shown that TS/A murine mammary adenocarcinoma cells, induced to express high surface expression of MHC class II molecules by stable transfection of CIITA, resulted in high rate (92%) of tumor rejection and tumor immunity to subsequent homologous tumor challenges. The immunological basis of tumor response is based on tumor-specific CD4+ T helper type 1 (Th1) in the priming phase and tumor-specific CD8+ T cells as the major effector cells. IL-12 is the crucial cytokine that drives Th1 polarization in conjunction with inducing strong cellular-based immune responses. We have previously shown in the same tumor model that a naked DNA IL-12 gene transfer was effective in preventing tumor angiogenesis in an immunopreventive approach when administrated at least 2 days prior to the tumor inoculation. Here we indicate that the combination of the two approaches in immunotherapy of established tumors is efficacious in delaying tumor growth but not in completely eradicating the tumor.

AB - We have previously shown that TS/A murine mammary adenocarcinoma cells, induced to express high surface expression of MHC class II molecules by stable transfection of CIITA, resulted in high rate (92%) of tumor rejection and tumor immunity to subsequent homologous tumor challenges. The immunological basis of tumor response is based on tumor-specific CD4+ T helper type 1 (Th1) in the priming phase and tumor-specific CD8+ T cells as the major effector cells. IL-12 is the crucial cytokine that drives Th1 polarization in conjunction with inducing strong cellular-based immune responses. We have previously shown in the same tumor model that a naked DNA IL-12 gene transfer was effective in preventing tumor angiogenesis in an immunopreventive approach when administrated at least 2 days prior to the tumor inoculation. Here we indicate that the combination of the two approaches in immunotherapy of established tumors is efficacious in delaying tumor growth but not in completely eradicating the tumor.

KW - Adenocarcinoma

KW - IL-12

KW - MHC-II

UR - http://www.scopus.com/inward/record.url?scp=36648999401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36648999401&partnerID=8YFLogxK

U2 - 10.1016/j.suronc.2007.10.045

DO - 10.1016/j.suronc.2007.10.045

M3 - Article

C2 - 18035537

AN - SCOPUS:36648999401

VL - 16

SP - 33

EP - 36

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

ER -